Keyphrases
Glucose-dependent Insulinotropic Polypeptide
100%
Competitive Antagonist
50%
Chemokine Receptor
44%
Glucagon
39%
C-C Chemokine Receptor Type 5 (CCR5)
33%
High Affinity
32%
Glucagon-like
29%
Receptor Antagonist
23%
Transmembrane
20%
Transmembrane Helix
20%
Somatostatin
19%
7TM Receptors
19%
Insulin
19%
Glucose Effect
19%
Truncated Forms
17%
Healthy Individuals
17%
Partial Agonist
17%
Hypoglycemia
16%
Specific Action
16%
Functional Complementation
16%
Activity State
16%
Placebo-controlled
16%
Type 2 Diabetic Patients
16%
CCR1
16%
BILF1
16%
Human Cytomegalovirus
16%
Evolutionary Pressure
16%
Type I Diabetes
16%
GIP Receptor
16%
Cerebrospinal Fluid
16%
Tumorigenic Effects
16%
GPR87
16%
Viral
16%
Co-agonist
16%
Gating Mechanism
16%
G Protein-coupled
16%
Conserved Regions
16%
Vasodilator
16%
Liraglutide
16%
DRY Motif
16%
Functional Comparison
16%
Disulfide Bridge
16%
Type 1 Diabetes Mellitus (T1DM)
16%
Nonhuman Primate
16%
Leucine
16%
Structural Diversity
16%
Glucos
16%
Pharmacology, Toxicology and Pharmaceutical Science
Gastric Inhibitory Polypeptide
83%
Gastric Inhibitory Polypeptide Receptor
69%
Competitive Antagonist
33%
Receptor
27%
Receptor Antagonist
23%
Guanine Nucleotide Binding Protein
19%
Glucagon-Like Peptide-1
18%
Partial Agonist
17%
Placebo
16%
Agonist-Antagonist
16%
Isoleucine
16%
Carcinogenesis
16%
Chemokine Receptor
16%
Beta Chemokine
16%
Biochemistry, Genetics and Molecular Biology
Gastric Inhibitory Polypeptide
50%
Gastric Inhibitory Polypeptide Receptor
50%
Chemokine Receptor
33%
G Protein
22%
Murine cytomegalovirus
16%
Receptor Antagonist
16%
Human cytomegalovirus
16%
Lymphocryptovirus
16%
G Protein Coupled Receptor
16%
Carcinogenesis
16%
CCR1
16%
CCR5
16%
Cell Transformation
16%
Disulfide
16%
